TP53 and endometrial cancer: Firstly, the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) study used immunohistochemistry for mismatch repair proteins, TP53 Tumor protein (p53), and POLE as surrogates of molecular markers and risk-stratified a large cohort of young women (n = 319) of less than 50 years of age and defined prognosis in this cohort [34].